Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women.

OBJECTIVES: This study aimed to assess the relationship between bone mineral density and genotypes of four polymorphisms in previously detected osteoporosis-candidate genes (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438) in postmenopausal Romanian women with primary osteoporosis.
METHODS: An analytical, prospective, transversal, observational, case-control study on 364 postmenopausal Romanian women was carried out between June 2016 and August 2017 in Cluj Napoca, Romania. Clinical data and blood samples were collected from all study participants. Four polymorphisms were genotyped using TaqMan SNP Genotyping assays, run on a QuantStudio 3 real-time PCR machine.
RESULTS: Women with TT genotype in FDPS rs2297480 had significantly lower bone mineral density values in the lumbar spine and total hip, and the presence of the T allele was significantly associated with the osteoporosis. Women carrying the CC genotype in LRP5 rs3736228 tend to have lower bone mineral density values in the femoral neck and total hip. No significant association was found for the genotypes of SOST rs1234612 or VKORC1 rs9934438.
CONCLUSIONS: Our study showed a strong association between bone mineral density and polymorphisms in the FDPS gene, and a borderline association with LRP5 and SOST polymorphisms in postmenopausal Romanian women with osteoporosis. No association was found for VKORC1.

Introduction

Osteoporosis (OP) is a common and complex skeletal disorder characterized by decreased bone mass and bone quality, which lead to an increase vulnerability to fragility fractures [1]. From a genetic perspective, the etiology of OP and fracture risk susceptibility is multifactorial, involving significant environmental influence together with genetic factors across numerous biologic processes, and it is thought that 60% to 80% of bone loss acceleration is due to genetic factors. [2]

More than 66 bone mineral density (BMD) loci have been studied in genome wide association studies (GWASs), confirming the highly polygenic nature of BMD variation. Although over the past decades there has been significant progress in identifying candidate genes involved in BMD, fracture and other related phenotypes, most of the genetic variants remain to be uncovered or validated in various ethnic groups.

To date, multiple single nucleotide polymorphisms (SNPs) in several genes have been associated to BMD, but the results are inconclusive and conflicting. As OP is a polygenic disease, and each bone phenotype (density, quality, metabolic rate) is the result of interaction among multiple genes, and the “essential” one, responsible for OP, is not yet identified despite using advanced methods [3,4].

One of the most important signaling pathways in bone in Wnt, which is crucial for bone development during embryogenesis and has a dual role in bone mass regulation, influencing both bone formation and resorption. The components of the Wnt pathway are proteins involved in cell proliferation, differentiation, and apoptosis of bone cells.[5] When cells are stimulated through the membrane receptors low-density lipoprotein receptor-related protein 5/6 (LRP5/6), the architecture of the multiprotein complex is modified, which inhibits b-catenin, leading to its translocation to the nucleus, where it initiates the transcription of target genes.[6] LRP5 is the most important membrane receptor of the Wnt signaling pathway and it was previously tagged in a genome-wide association study to be associated with OP.[7] LRP5 inactivation caused by mutation is responsible for osteoporosis-pseudoglioma syndrome, in which low bone mass and fractures occur.[8] Also, there are several naturally occurring inhibitors of Wnt signaling, such as Dickkopf (DKK) and sclerostin (SOST) proteins that inactivate signaling from LRP5/6 receptors. Sclerostin, encoded by the SOST gene, antagonizes Wnt signaling in both osteocytes and osteoblasts by binding to the LRP5/6 coreceptor and preventing bone formation.[9,10] High-bone-mass syndromes are thought to be caused by inactivating mutations of SOST (sclerosteosis and van Buchem’s disease).[11] Animal studies have indicated that sclerostin inhibition increases bone mass by stimulating bone formation and inhibiting bone resorption.[12]

The discovery of mevalonate pathway’s role as the target of the antiresorbtive agents from the amino-bisphosphonates (N-BP) class, used in postmenopausal OP treatment, revealed other important genes to be considered as candidate genes, like farnesyl diphosphate synthase (FDPS) or geranylgeranyl pyrophosphate synthase (GGPS1), which maintain the resorption activity of the osteoclasts. FDPS is a key-enzyme of the mevalonate pathway and is a well recognised target of several N-BPs, making it worthy of being studied. [13-19]

Also, even though its hemostatic effect and implication in warfarin sensitivity are well known, there has been evidence that vitamin K also plays an important role in maintaining bone strength and that mutations in the vitamin K epoxy reductase (VKORC1) gene may modify the gamma-carboxylation of osteocalcin and may influence BMD [20-22].

Today, it is well established that OP is a multifactorial complex disorder, whose pathogenesis is due to the interaction of various genetic determinants regulating bone and mineral metabolism with “non-skeletal” risk factors that could influence fall risk (e.g. muscle strength, balance, visual acuity), environmental influences and lifestyle [23]. However, to date no gene has been definitely identified as a major gene for OP.

The purpose of the present study is to evaluate the relation between BMD and genotypes of four SNPs in previously reported osteoporosis candidate-genes (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438) in a cohort of postmenopausal Romanian women.

Material and methods

Study population

An analytical, prospective, transversal, observational, case-control study on 364 postmenopausal Romanian women was carried out between June 2016 and August 2017. All the women included in the study were recruited either from the inpatient clinic or during routine outpatient visit in the Clinical Rehabilitation Hospital in Cluj-Napoca, Romania.

The inclusion criteria was as follows: women, at least 45 years old, that had been menopausal for at least 2 years and had a recent diagnosis of osteoporosis or normal density result on BMD measurement using dual-energy X-ray absorbtiometry (DEXA). The women included in the study were divided into two groups: osteoporosis (n = 228) and healthy age-matched controls (n = 136). Patients with history of metabolic bone diseases (e.g. hyperparathyroidism, osteomalacia, Paget disease), malignancy, bone metastasis and those treated with drugs that influence bone metabolism (e.g. anti-osteoporotic drugs or vitamin K antagonists) were excluded from the study.

Clinical data was collected by interview and from the medical documents of each patient: age, body mass index, years since menopause, lumbar spine (L1-L4), femoral neck and total hip BMD. Furthermore, a 2 ml EDTA vial of peripheral blood was collected from each study participant for the genetic testing.

The study was approved by the Ethics Committee of the University of Medicine and Pharmacy “Iuliu Hațieganu” Cluj-Napoca (approval no. 248/09.06.2016). All participants were informed of the characteristics of the study and all gave signed informed consent regarding the genetic testing and clinical data collection prior to inclusion.

SNP genotyping

Genomic DNA was obtained from peripheral blood withdrawn on EDTA, using commercially available kits (Quick gDNA MiniPrep kit, Zymo Research, USA; PureLink Genomic DNA Mini Kit, Invitrogen, Thermo Fisher, USA). We genotyped four SNPs (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438) in all patients and controls using the real-time PCR technique. Standard, predesigned TaqMan SNP genotyping assays, containing all the primers and probes needed for genotyping, were purchased from Thermo Fisher (codes C___2737970_10, C__25752205_10, C___7566033_10, C__30204875_10). All the genotyping were performed according to manufacturer’s instructions. The reaction mix contained 10 μl of 2xTaqMan Genotyping Master Mix (Applied Biosystems, Thermo Fisher, USA), 0.5 μl of the corresponding 40xTaqMan SNP genotyping assay, approximately 25 ng of genomic DNA and free-nucleases water to the final volume of 20 μl. The same amplification program was used for all the genotyping, consisting in a pre-read stage of 30 seconds (s) at 60°C, hold stage of 10 minutes (min) at 95°C, followed by the PCR stage, consisting of 40 cycles, each comprising 15 s at 95°C and 1 min at 60°C, and a post-read stage of 30 s at 60°C. All the experiments were run on a QuantStudio 3 real-time PCR machine (Applied Biosystems, Thermo Fisher, USA).

Statistical analysis

Statistical analysis was performed using MedCalc Statistical Software version 18.6 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2018). Qualitative data were characterized by frequency and percent. Quantitative data were described by mean and standard deviation or median and 25–75 percentiles, depending on the normality of distribution at Kolmogorov Smirnov test. Differences between groups were tested using the chi-square or Mann-Whitney, whenever appropriate (t-test, Fischer). A p-value <0.05 was considered statistically significant. The size sample estimation was calculated by assessing the distribution of the TT genotype for FDPS rs2297480 SNP in a group of 23 patients (52.2%) with osteoporosis and 13 controls (38.5%). For a type I error of 0.05 and a type II error of 0.20, we calculated a number of 162 controls and 290 patients.

Results

A total of 364 patients met the inclusion criteria and were included in the study to be genotyped, of which 228 had a diagnosis of OP and were compared to 136 age-matched healthy controls. The mean age in the osteoporosis group was 65.5 years (±7.39), and 63.45 (± 8.16) in the control group, respectively. The osteoporosis group had signficantly more years of amenorrhea than the control group, lower BMD values at all measured sites and a higher fracture risk (all p<0.05).

The main characteristics of the women included in the study are shown in Table 1.

Table 1

Clinical characteristics of women included in the study.

Variables	Osteoporosisn = 228	Controlsn = 136	p-value
Age, mean ± SD [years]	65.5 ± 7.39	63.45 ± 8.16	0.014
BMI, mean ± SD [kg/m2]	27.05 ± 4.74	30.56 ± 5.40	< 0.001
Age at menopause, mean ± SD [years]	47.26 ± 4.84	48.35 ± 4.88	0.045
Time of amenorrhea, mean ± SD [years]	18.25 ± 8.36	15.08 ± 8.82	0.001
Previous fragility fracture (vertebral, hip, wrist, humerus), n (%)	132 (57.9)	0 (0)	-
Current smoking, n (%)	10 (4.4)	6 (4.4)	0.991
Alcohol consumption > 3 units/day, n (%)	3 (1.3)	0 (0)	-
Parent fractured hip, n (%)	13 (5.6)	8 (5.8)	0.943
Lumbar spine (L1-L4) BMD, mean ± SD [g/cm2]	0.851 ± 0.11	1.116 ± 0.15	< 0.001
Femoral neck BMD, mean ± SD [g/cm2]	0.751 ± 0.10	0.969 ± 0.21	< 0.001
Total hip BMD, mean ± SD [g/cm2]	0.791 ± 0.5	0.968 ± 0.21	<0.001
FRAX—10 year risk of major osteoporotic fracture, mean ± SD [%]	8.04 ± 4.68	4.34 ± 2.47	0.005
FRAX—10 year risk of hip fracture, mean ± SD [%]	2.76 ± 2.97	0.82 ± 1.47	< 0.001

The distribution of the FDPS rs2297480, LRP5 rs3736228, SOST rs1234612 and VKORC1 rs9934438 genotypes and allele frequencies in the study population (n = 364) are shown in Table 2.

Table 2

Allelic and genotypic frequencies of the SNPs in the study population (n = 364).

Gene	SNP	Genotypes (%)			Allele (%)
FPDS	rs2297480	TT	GT	GG	T	G
		222 (60.99)	124 (34.07)	18 (4.95)	568 (78)	160 (22)
LRP5	rs3736228	CC	CT	TT	C	T
		257 (70.6)	103 (28.3)	4 (1.1)	617 (85)	111 (15)
SOST	rs1234612	TT	CT	CC	T	C
		183 (50.27)	142 (39.01)	39 (10.71)	508 (70)	220 (30)
VKORC1	rs9934438	GG	AG	AA	G	A
		126 (34.62)	156 (42.86)	82 (22.53)	408 (56)	320 (44)

Women carrying the TT genotype of FDPS rs2297480 have significantly lower BMD values in the lumbar spine and total hip than the heterozygous GT or homozygous GG (p = 0.006 and p = 0.03, respectively), but not in the femoral neck (p = 0.179) (Table 3).

Table 3

Bone mineral density values among genotypes (n = 364).

Gene (SNP)	Genotype	BMD L1-L4 g/cm2 (IQR)	BMD FEMORAL NECK g/cm2 (IQR)	BMD TOTAL HIP g/cm2 (IQR)
FDPS rs2297480	GG	0.910 (0.804; 1.023)	0.840 (0.699; 0.925)	0.865 (0.747; 1.030)
	GT	0.981 (0.852; 1.102)	0.803 (0.725; 0.885)	0.882 (0.779; 0.997)
	TT	0.865 (0.778; 1.091)	0.774 (0.705; 0.873)	0.833 (0.746; 0.939)
	p-value	0.006	0.179	0.030
LRP5 rs3736228	TT	0.877 (0.669; 1.053)	0.782 (0.711; 0.861)	0.832 (0.756; 0.945)
	CT	0.943 (0.788; 1.099)	0.825 (0.714; 0.918)	0.895 (0,771; 1.019)
	CC	0.924 (0.836; 1.061)	0.715 (0.635; 0.747)	0.810 (0.644; 0.882)
	p-value	0.717	0.028	0.014
SOST rs1234612	CC	1.004 (0.897; 1.085)	0.792 (0.734; 0.891)	0.896 (0.742; 1.008)
	CT	0.941 (0.838; 1.076)	0.787 (0.702; 0.870)	0.850 (0.759; 0.950)
	TT	0.910 (0.812; 1.046)	0.799 (0.714; 0.886)	0.837 (0.757; 0.965)
	p-value	0.124	0.596	0.679
VKORC1 rs9934438	AA	0.959 (0.848; 1.120)	0.803 (0.711; 0.931)	0.860 (0.770; 1.019)
	AG	0.910 (0.812; 1.055)	0.792 (0.702; 0.870)	0.832 (0.742; 0.948)
	GG	0.926 (0.823; 1.042)	0.794 (0.721; 0.873)	0.847 (0.771; 0.963)
	p-value	0.086	0.367	0.133

After dividing the patients into groups, analysis of the codominant model was performed. Codominant models hypothesize that the major allele homozygotes, the heterozygotes or the minor allele homozygotes are associated with the lowest, the intermediate, and the highest risk, respectively, or they are associated with the highest, the intermediate, and the lowest risk, respectively.

Results show that when analyzing the codominant model, the TT genotype of rs2297480 SNP continues to be significantly associated with OP risk (OR = 2.1; 95% CI = 1.4–3.3; p-value<0.05), while the GT genotype had the lowest risk (OR = 0.4; 95% CI = 0.3–0.7; p-value = 0.001). Furthermore, the presence of the T allele was significantly associated with OP in the group analysis (p = 0.005) (Table 4).

Table 4

Allelic and genotypic distribution between osteoporotic women and controls.

Gene	Polymorphism	Model/alleles	Genotypes, alleles	Osteoporosis (%)(n = 228)	Controls (%)n = 136	OR [95% CI]	p-value
FDPS	rs2297480	Codominant	GG	10 (4.4)	8 (5.9)	0.7 [0.2–1.9]	0.524
			GT	63 (27.6)	61 (44.9)	0.4 [0.3–0.7]	0.001
			TT	155 (68)	67 (49.3)	2.1 [1.4–3.3]	<0.05
		Major allele	T	373 (81.8)	195 (71.7)	-	0.005
		Minor allele	G	83 (18.2)	77 (28.3)	-	0.127
LRP5	rs3736228	Codominant	CC	169 (74.1)	88 (64.7)	1.5 [0.9–2.4]	0.05
			CT	56 (24.6)	47 (34.6)	0.6 [0.3–0.9]0.6 [03.-0.9]	0.041
			TT	3 (1.3)	1 (0.7)	1.8 [0.1–17.4]	0.612
		Major allele	C	394 (86.4)	223 (82)	-	0.143
		Minor allele	T	62 (13.6)	49 (18)	-	0.527
SOST	rs1234612	Codominant	CC	19 (8.3)	20 (14.7)	0.5 [0.2–1]	0.057
			CT	88 (38.6)	54 (39.7)	0.9 [0.6–1.4]	0.834
			TT	121 (53.1)	62 (45.6)	1.3 [0.8–2]	0.167
		Major allele	T	330 (72.4)	178 (65.4)	-	0.101
		Minor allele	C	126 (27.6)	94 (34.6)	-	0.266
VKORC1	rs9934438	Codominant	AA	46 (20.2)	36 (26.5)	0.7 [0.4–1.1]	0.164
			AG	101 (44.3)	55 (40.4)	1.1 [0.7–1.8]	0.472
			GG	81 (35.5)	45 (33.1)	1.1 [0.7–1.7]	0.636
		Major allele	G	263 (57.7)	145 (53.3)	-	0.391
		Minor allele	A	193 (42.3)	127 (46.7)	-	0.438

As for LRP5 rs3736228 SNP, the homozygous CC have significantly lower BMD values in the femoral neck and total hip than the CT or TT genotypes (p = 0.028 and p = 0.014), but not in the lumbar spine region (p = 0.717) (Table 3). In the codominant model of the groups analysis, this association continues to reach statistical significance in the OP group (OR = 1.5; 95% CI = 0.9–2.4; p = 0.05), while the heterozygous CT had the lowest risk (OR = 0.6; 95% CI = 0.3–0.9; p = 0.041). Furthermore, no association was found for the C allele and OP phenotype (p = 0.143) (Table 4).

No genotype or allele of SOST rs1234612 were found to be significant associated with OP or low BMD (all p>0.05) (Tables 3 and 4).

When analyzing BMD values between genotypes of VKORC1 rs9934438, no statistical significance was found, except for the heterozygous AG which showed a slight trend of having lower BMD values in the lumbar spine (p = 0.086) (Table 3). The model and allelic analysis revealed no significant statistical associations between groups (all p>0.05) (Table 4).

Discussion

Even though in the last two decades researchers have continuously searched for the role of genetic factors in the pathogenesis of bone loss, up to date, there is no conclusive etiologic information about OP in this area.

FDPS is one of the key-enzymes involved in the mevalonate pathway and it was identified as the main biochemical target of N-BPs [24]. Our research showed a significant association between the presence of the major allele T and osteoporosis (p = 0.005). Also, genotype TT of rs2297480 SNP had significantly lower BMD values in the lumbar spine and total hip (both p<0.05). These results are consistent with the findings of Levy at al. [17], who evaluated the same FDPS polymorphism and found a strong association between the presence of the major allele C and low BMD in elderly American women. Marini et al. [18], Olmos et al. [19] and Massart et al [25] evaluated the relation between genotypes of rs2297480 polymorphism and BMD in Caucasian women, but did not find an association with baseline BMD values. The genotype frequencies are similar to those reported in the American [17], Danish [18], Spanish [19] and Italian [25] population. The current findings are significant for Romanian postmenopausal women, as the T allele and the TT genotype are the most frequent (78% and 60.99%, respectively).

It is known that genes involved in the Wnt pathway are important players in skeletal homeostasis [26]. Polymorphisms in the LRP5 gene have been previously linked to lumbar spine BMD in adults in multiple studies. Canto-Cetina et al. [27] found a significant association between rs3736228 polymorphism and variations in all BMD sites in Maya-Mestizo women. Interestingly, no significant association of the same SNP with BMD was found in the Slovenian [28], Mexican [29] or Chinese [30] population. In the present research, the CC and CT genotypes of LRP5 rs3736228 were associated with OP (p = 0.05 and p = 0.041, respectively). Also, postmenopausal women carrying the CC genotype have significantly lower BMD values in the femoral neck and total hip (both p<0.05). Interestingly, in an Italian population, LRP5 rs3736228 CC genotype tended to have higher BMD values than TT genotype in all BMD sites [25]. And Markatseli et al. [31] reported in a cohort of Greek peri- and postmenopausal women that the presence of CT/TT genotype is consistent with lower lumbar spine BMD. Ezura et al. [32] analyzed rs37362288 genotypes in relation to BMD in adult Japanese women. They found that the homozygous carrying the minor T allele had the lowest BMD scores, and that homozygous carrying the major C allele had the higher BMD. Interestingly, even though the genotypic distribution in the present study is similar to that reported in the Japanese [32], Italian [25] or Greek [31] women, our findings suggest that osteoporosis-risk genotype could be the homozygous CC in postmenopausal Romanian women.

There has been evidence that other Wnt genes, like SOST, influence BMD in the general population [33,34]. Valero et al. [35] found that several polymorphisms in the 5’ region of the SOST gene are associated with BMD in postmenopausal Spanish women. The CTT haplotype at loci rs1234612 was significantly associated with lumbar spine BMD, but not in the femoral neck area. The present study found no association between genotypes and BMD values (all p>0.05). Zhang et al. [36] found that the rs1234612 and the SOST haplotype GGTGGATC were associated with adjusted total hip BMD in a large sample of postmenopausal Chinese women. On the contrast, He and al. [37] and Balemans et al. [38] did not find any association between SOST gene polymorphisms and BMD in postmenopausal and perimenopausal women, respectively. Velasquez-Cruz et al. [39] concluded that SOST polymorphisms contribute to total hip and femoral neck BMD in postmenopausal Mexican-mestizo women. Zhou et al. [36] evaluated several SOST polymorphisms regarding treatment response to N-BPs therapy. They found a strong correlation between subjects with homozygous common alleles of rs1234612 and rs851054 and baseline BMD in the lumbar spine. In our study, genotype frequencies of SOST rs1234612 were not different than previously reported in the Asian [36,40] population.

There has been evidence that vitamin K plays an important role in maintaining bone strength by acting as a cofactor of the gamma-carboxylase enzyme which activates Vitamin K-dependent proteins in bone, like osteocalcin [41,42]. The VKORC1 gene is highly polymorphic and mutations in the VKORC1 gene may modify the gamma-carboxylation of osteocalcin and may influence BMD [20,21]. The effects of VKORC1 gene on bone have been investigated in several studies. Crawford et al. [43] showed an association of several SNPs in the VKORC1 gene with BMD in African-Americans. Also, Holzer et al. [44] made a significant association between 3673 G>A genotype and BMD, showing that the homozygous AA had lower BMD values than AG or GG. In the current research, the heterozygous AG tended to have lower BMD values in the lumbar spine area, but it did not reach statistical significance (p = 0.086). Interestingly, Fodor et al. [20] found that the TT genotype of VKORC1 1173C>T was the most frequent in another cohort of postmenopausal Romanian women with OP or osteopenia. Also, a recent study conducted on a Turkish population showed no association between a polymorphism in the VKORC1 gene and BMD [21]. In our study, the genotype frequencies of the rs9934438 polymorphism were similar to those previously reported in the Romanian [20,22] population. However, relevant studies demonstrating the relationship of this gene to bone biology are still lacking.

This study has several limitations. First, it included only white women and it is unclear if the results can be extrapolated to women of different ethnicity. Secondly, the cohort size was modest, as genetic investigation requires higher number of subjects to achieve sufficient statistical power. And thirdly, the study design was clinic and volunteer based, not population based, therefore potential biases remain.

To our knowledge, this is the first study to detect a positive or negative association between four SNPs in different genes with BMD in a Romanian cohort of postmenopausal women with OP. To date, only one of the SNPs included in this study has been evaluated before in a Romanian population regarding its relation with BMD (VKORC1 rs9934438) [23]. Also, it is important to mention that the Romanian population is relatively understudied with regards to OP genetics, and the results from this study are potentially of interest for future meta-analyses. Because of the polygenic nature of OP, few genes have major impact on bone metabolism or homeostasis and multiple genes have minor effects, making the classical gene-disease association approach limited, as it mostly lead to inconclusive or controversial results. Regardless of this, data obtained from the current study could be important to Romanian postmenopausal women, as the burden of OP and osteoporosis-related fractures is increasing in Romania, as in other European countries [45].

Conclusions

Our study showed a strong association between osteoporosis and TT genotype of FDPS rs2297480, and with CC genotype of LRP5 rs3736228. No statistical significance was found between genotypes of SOST rs1234612 and VKORC1 rs9934438 with BMD in postmenopausal Romanian women with osteoporosis.

Table with genotyping data and bone mineral density.

(PDF)

Click here for additional data file.

21 Oct 2019

PONE-D-19-23734

Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women

PLOS ONE

Dear Dr. Ciubean,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

ACADEMIC EDITOR:  Though the reviewers finds the study is interesting, the authors should address the editorial comments as noted below to further improve the manuscript.  Particularly, they should provide specifics/details and clarify rationale appropriately to study the gene polymorphisms associated with bone anabolic and antiresorptive agents used to treat postmenopausal osteoporosis.

We would appreciate receiving your revised manuscript by Dec 05 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Dr. Sakamuri V. Reddy

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please provide a sample size and power calculation in the Methods, or discuss the reasons for not performing one before study initiation.

Additional Editor Comments (if provided):

The authors have examined the occurrence of polymorphisms in FDPS, LRP5, SOST and VKORC1 genes with respect to bone mineral density (BMD) in postmenopausal Romanian women. The results showed a strong correlation of BMD and polymorphisms in FDPS (farnesyl diphosphate synthase) gene, but a modest association with LRP5 and SOST genes in postmenopausal Romanian women with osteoporosis and no association with VKORC1. Specific comments to further improve the manuscript are: Introduction-noted very briefly. Please clarify the source and function of SOST and LRP5 genes in bone remodeling with citations appropriately. For ex., a rationale for genes examined ie anti-resorptive and anti-anabolic. Also, clarify SOST gene product Sclerostin protein is primarily produced by the osteocyte has anti-anabolic effect on bone formation. Methods-SNP genotyping is described very briefly, and no details of PCR conditions given. Results-no rationale given for experiments conducted and this section is noted briefly with no details. References-correct ref#29, follow the journal format ex., remove the month, number in refs etc..

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This is an interesting report on distribution of 4 osteoporosis genes and their association with osteoporosis in a Romanian women cohort. Overall results are interesting and confirmatory. The paper is well written and contributes to the field of genetics of osteoporosis

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

11 Nov 2019

Dear Reviewers,

Below you have the responses to the points raised during the review process.

1. Introduction-noted very briefly. Please clarify the source and function of SOST and LRP5 genes in bone remodeling with citations appropriately. For ex., a rationale for genes examined ie anti-resorptive and anti-anabolic. Also, clarify SOST gene product Sclerostin protein is primarily produced by the osteocyte has anti-anabolic effect on bone formation.

Author response: The introduction has been updated accordingly.

“ One of the most important signaling pathways in bone in Wnt, which is crucial for bone development during embryogenesis and has a dual role in bone mass regulation, influencing both bone formation and resorption. The components of the Wnt pathway are proteins involved in cell proliferation, differentiation, and apoptosis of bone cells.[5] When cells are stimulated through the membrane receptors low-density lipoprotein receptor-related protein 5/6 (LRP5/6), the architecture of the multiprotein complex is modified, which inhibits b-catenin, leading to its translocation to the nucleus, where it initiates the transcription of target genes.[6] LRP5 is the most important membrane receptor of the Wnt signaling pathway and it was previously tagged in a genome-wide association study to be associated with OP.[7] LRP5 inactivation caused by mutation is responsible for osteoporosis-pseudoglioma syndrome, in which low bone mass and fractures occur.[8] Also, there are several naturally occurring inhibitors of Wnt signaling, such as Dickkopf (DKK) and sclerostin (SOST) proteins that inactivate signaling from LRP5/6 receptors. Sclerostin, encoded by the SOST gene, antagonizes Wnt signaling in both osteocytes and osteoblasts by binding to the LRP5/6 coreceptor and preventing bone formation.[9.10] High-bone-mass syndromes are thought to be caused by inactivating mutations of SOST (sclerosteosis and van Buchem’s disease).[11] Animal studies have indicated that sclerostin inhibition increases bone mass by stimulating bone formation and inhibiting bone resorption.[12]”

2. Methods-SNP genotyping is described very briefly, and no details of PCR conditions given.

Author response: The PCR conditions has been added to the Material and Methods section

“Genomic DNA was obtained from peripheral blood withdrawn on EDTA, using commercially available kits (Quick gDNA MiniPrep kit, Zymo Research, USA; PureLink Genomic DNA Mini Kit, Invitrogen, Thermo Fisher, USA). We genotyped four SNPs (FDPS rs2297480, LRP5 rs3736228, SOST rs1234612, VKORC1 rs9934438) in all patients and controls using the real-time PCR technique. Standard, predesigned TaqMan SNP genotyping assays, containing all the primers and probes needed for genotyping, were purchased from Thermo Fisher (codes C___2737970_10, C__25752205_10, C___7566033_10, C__30204875_10). All the genotyping were performed according to manufacturer’s instructions. The reaction mix contained 10 μl of 2xTaqMan Genotyping Master Mix (Applied Biosystems, Thermo Fisher, USA), 0.5 μl of the corresponding 40xTaqMan SNP genotyping assay, approximately 25 ng of genomic DNA and free-nucleases water to the final volume of 20 μl. The same amplification program was used for all the genotyping, consisting in a pre-read stage of 30 seconds (s) at 60°C, hold stage of 10 minutes (min) at 95°C, followed by the PCR stage, consisting of 40 cycles, each comprising 15 s at 95°C and 1 min at 60°C, and a post-read stage of 30 s at 60°C. All the experiments were run on a QuantStudio 3 real-time PCR machine (Applied Biosystems, Thermo Fisher, USA).”

3. Results-no rationale given for experiments conducted and this section is noted briefly with no details.

Author response: The rationale behind the experiments have been added

” After dividing the patients into groups, analysis of the codominant model was performed. Codominant models hypothesize that the major allele homozygotes, the heterozygotes or the minor allele homozygotes are associated with the lowest, the intermediate, and the highest risk, respectively, or they are associated with the highest, the intermediate, and the lowest risk, respectively.”

4. References-correct ref#29, follow the journal format ex., remove the month, number in refs etc..

Author response: all references have been modified accordingly.

5. Have the authors made all data underlying the findings in their manuscript fully available? Reviewer response: No

Author response: An Excel file with the raw data has been uploaded with the manuscript files

In the name of all the authors, we thank you for the peer-review process, and we hope the modifications are sufficient and the article is ready to be published in its currents form. If any further clarifications are required, we are happy to give them.

Sincerely,

Dr. Alina Deniza Ciubean

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

13 Nov 2019

Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women

PONE-D-19-23734R1

Dear Dr. Ciubean,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Dr. Sakamuri V. Reddy

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

19 Nov 2019

PONE-D-19-23734R1

Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women

Dear Dr. Ciubean:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Sakamuri V. Reddy

Academic Editor

PLOS ONE